Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000091

Drug Information
NameZafirlukast
Synonymscyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate; ICI 204,219; CID5717; C07206; ICI 204219; L001011; MLS001424064; SAM001246577; STK646780; ZINC00896717; 107753-78-6; Accolate, Accoleit, Vanticon, Zafirlukast; NCGC00164547-01; Carbamic acid, (3-((2-methoxy-4-((((2-methylphenyl)sulfonyl)amino)carbonyl)phenyl)methyl)-1-methyl-1H-indol-5-yl)-, cyclopentyl ester; Accolate (TN); D00411; LS-50025; Novartis brand of zafirlukast; C062735; Zafirlukast [USAN:BAN:INN]; Aeronix; DB00549; Cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate; HMS2089J10; MLS000759421-02; Zeneca brand of zafirkulast; cyclopentyl [3-(2-methoxy-4-{[(2-methylphenyl)sulfonyl]carbamoyl}benzyl)-1-methyl-1H-indol-5-yl]carbamate; CHEMBL603; BIDD:GT0267; cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate; AC1L1KZB; Bio-0152; 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; zafirlukast; MolPort-003-850-873; MLS000759421; 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide; Accoleit; SMR000466316; Zafirlukast (JAN/USAN/INN); C31H33N3O6S; CHEBI:10100; 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide; Respix; cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate; Olmoran; CPD000466316; AstraZeneca brand of zafirlukast; I06-0398; UNII-XZ629S5L50; S1633_Selleck; Zafirst; ICI-204219; Accolate; Menarini brand of zafirlukast; HMS2051F12
Trade NameAccolate; Accoleit; Vanticon
CompanyAstraZeneca plc
IndicationAsthma
[ICD9: 493   ICD10: J45]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21
(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-
25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,3
6)(H,33,35)
InChIKeyYEEZWCHGZNKEEK-UHFFFAOYSA-N
Canonical SMILESCC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)
OC5CCCC5)C)OC    
Therapeutic ClassAnti-Asthmatic Agents
CAS NumberCAS 107753-78-6
FormulaC31H33N3O6S
PubChem Compound IDCID 5717.
PubChem Substance IDSID 9415.
ChEBI10100;
SuperDrug ATC IDR03DC01
SuperDrug CAS ID107753786;
TargetCysteinyl leukotriene receptor 1Antagonist[2][3][1]
Ref 1Role of antileukotriene agents in asthma therapy. J Am Osteopath Assoc. 2000 Jan;100(1):32, 37-43. To Reference
Ref 2Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45. To Reference
Ref 3Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543